- The top drugs, companies and therapy areas to 2030
- The rise and rise of GLP-1 drugs
- The fast-changing role of Chinese biotechs
- How loss of exclusivity will impact blockbuster therapies
Evaluate’s latest forecasts show a growth rate of over 7% over the next five years with top therapy areas likely to reach 17% growth.
Share:
But the picture is much more complicated that that. In this webinar, our experts will discuss the latest findings from our annual World Preview report to unpick some of the key trends, thorny challenges, and strategic opportunities ahead.
